- The final clinical trial data review for Mesoblast’s (ASX:MSB) heart disease treatment has now been completed
- The phase three trial tested outcomes associated with Revascor, a treatment being developed for advanced and end-stage chronic heart disease
- The independent Data Monitoring Committee reviewed data from over 500 participants and gave the go-ahead for final patient visits
- Results for the phase three trial are expected by mid-2020
- Shares in Mesoblast rose 1.04 per cent to be worth $1.94 apiece at market close
The final clinical trial data review for Mesoblast’s (ASX:MSB) heart disease treatment has now been completed.
The independent Data Monitoring Committee overseeing the phase three trial for advanced chronic heart failure held its tenth and final meeting today.
The committee reviewed primary and secondary endpoint data from 566 patients across North America, as well as safety data. It then recommended Mesoblast continue the trial as planned and complete final patient visits.
These visits are planned to be completed in January 2020. Final study results are expected in mid-2020.
The phase three trial
The trial tested outcomes associated with Revascor, a treatment being developed to treat advanced and end-stage chronic heart disease.
Specifically, the company defines the trial’s objective as to evaluate Revascor’s ability to reduce the primary endpoint of recurrent non-fatal heart failure-related major adverse cardiac events and to delay or prevent disease progression to end-stage heart failure and terminal cardiac events.
Yesterday, the company announced it has exceeded the number of primary endpoint events required to complete the trial.
Revascor works by injecting 150 million mesenchymal precursor cells (MPCs) directly into the heart.
Specific interactions with the damaged tissue triggers the MPCs to release various factors. Preclinical data shows these factors induce cardiac recovery through multiple pathways.
Shares in Mesoblast rose 1.04 per cent to be worth $1.94 apiece at market close.